Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
about
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsBusulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.Children's Oncology Group's 2013 blueprint for research: neuroblastoma.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
P2860
Q34409335-28EDB15E-EFAA-4057-8E6A-6BACDD885267Q35043574-2C16E0AE-EED5-460D-8558-E5894B2FB324Q35073850-3DFB9357-D693-476D-928E-7C6E85D5C6CFQ36125427-912CFCDB-6EAE-4C78-8F31-98CEF1B1A80BQ36703516-E54B2F52-E669-415E-A5DB-25713AF79BD5Q36892839-82A33F7D-439E-4667-9865-EB0A86F59E72Q36987975-F4BA4054-F5A4-4741-ACB1-FD5DC29B27E8Q37461968-C3380138-B697-4E01-9F80-52DF3EB90D25Q37624344-805AF236-7BBC-462F-BA46-23339E93F79DQ38048241-D11F1F8C-B8D2-4045-B707-0123533EC4D8Q38068818-9058C56A-14A5-4539-9EDA-74F99BA73982Q38847841-51DEB045-D506-4D3F-A925-652DA4FFB474Q39783369-2F508AD1-6C54-40BC-AF02-4DD3A43E2518Q39865674-1C1BD2F8-ED2A-4951-A549-114A9A66BF58Q40050078-6472F7FF-3FCA-4B93-8D55-41D1FF033873Q40075349-AB2D7946-72B0-458E-BD42-086DB8F9DCE2Q40367223-6D51BE89-4A6F-4F20-ABD7-AB1CC953B794Q43429437-BF7E59A2-8114-4BBA-8C61-65F74BB01458Q44161848-C52046BC-AAB5-4CB3-AE57-9978B01A6F9CQ48239404-F4DEE997-63F3-4B4E-8D62-294B67C06B93Q49276207-E200D317-AC19-4E06-80F0-213A08E07DCEQ50043715-91F3AD1F-A38F-4B8E-BD24-6467638305EDQ50924228-8F88A686-134B-4E50-B892-19F3FD16207FQ52690736-B811515B-328C-480F-8075-CB36F1B7997C
P2860
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Busulfan pharmacokinetics foll ...... of the HR-NBL-1/SIOPEN trial.
@en
Busulfan pharmacokinetics foll ...... of the HR-NBL-1/SIOPEN trial.
@nl
type
label
Busulfan pharmacokinetics foll ...... of the HR-NBL-1/SIOPEN trial.
@en
Busulfan pharmacokinetics foll ...... of the HR-NBL-1/SIOPEN trial.
@nl
prefLabel
Busulfan pharmacokinetics foll ...... of the HR-NBL-1/SIOPEN trial.
@en
Busulfan pharmacokinetics foll ...... of the HR-NBL-1/SIOPEN trial.
@nl
P2093
P1476
Busulfan pharmacokinetics foll ...... t of the HR-NBL-1/SIOPEN trial
@en
P2093
D Valteau-Couanet
R Ladenstein
P304
P356
10.1016/J.EJCA.2012.05.020
P577
2012-06-26T00:00:00Z